ATE466588T1 - Bakteriophagen- und prophagen-proteine in der krebsgentherapie - Google Patents

Bakteriophagen- und prophagen-proteine in der krebsgentherapie

Info

Publication number: ATE466588T1
Authority: AT; Austria
Prior art keywords: polypeptide; bacteriophage; gene therapy; cancer gene; cell death
Prior art date: 2004-07-20

Application number

AT05772001T

Other languages

English (en)

Inventor

Udo Blaesi

Christine Hohenadl

Original Assignee

Ziel Biopharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-20

Filing date

2005-07-20

Publication date

2010-05-15

2005-07-20 Application filed by Ziel Biopharma Ltd filed Critical Ziel Biopharma Ltd

2010-05-15 Application granted granted Critical

2010-05-15 Publication of ATE466588T1 publication Critical patent/ATE466588T1/de

Links

108090000623 proteins and genes Proteins 0.000 title abstract 2
102000048850 Neoplasm Genes Human genes 0.000 title 1
108700019961 Neoplasm Genes Proteins 0.000 title 1
238000001415 gene therapy Methods 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
241001515965 unidentified phage Species 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
210000004102 animal cell Anatomy 0.000 abstract 2
230000030833 cell death Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000001939 inductive effect Effects 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000035755 proliferation Effects 0.000 abstract 2
108091026890 Coding region Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT05772001T 2004-07-20 2005-07-20 Bakteriophagen- und prophagen-proteine in der krebsgentherapie ATE466588T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04017128A EP1618886A1 (de)	2004-07-20	2004-07-20	Bacteriophage- und Prophage-Proteine in der Krebs-Gen-Therapie
PCT/EP2005/053533 WO2006008312A1 (en)	2004-07-20	2005-07-20	Bacteriophage and prophage proteins in cancer gene therapy

Publications (1)

Publication Number	Publication Date
ATE466588T1 true ATE466588T1 (de)	2010-05-15

Family

ID=34925838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05772001T ATE466588T1 (de)	2004-07-20	2005-07-20	Bakteriophagen- und prophagen-proteine in der krebsgentherapie

Country Status (13)

Country	Link
US (1)	US20090117084A1 (de)
EP (2)	EP1618886A1 (de)
JP (1)	JP2008506411A (de)
KR (1)	KR20070036185A (de)
CN (1)	CN1988913A (de)
AT (1)	ATE466588T1 (de)
AU (1)	AU2005263771A1 (de)
CA (1)	CA2572832A1 (de)
DE (1)	DE602005021159D1 (de)
EA (1)	EA012120B1 (de)
NO (1)	NO20070485L (de)
NZ (1)	NZ553196A (de)
WO (1)	WO2006008312A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8492333B2 (en) *	2010-02-22	2013-07-23	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Peptides and methods for inducing cell death
CN102994456B (zh) *	2011-09-15	2016-06-15	蔡志明	一种人工合成的s13噬菌体及其应用
US12076352B2 (en) *	2018-06-19	2024-09-03	Glaxosmithkline Biologicals Sa	Immunogenic composition
US20240277791A1 (en) *	2021-06-11	2024-08-22	Integrated Pharma Services, Llc	Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001263408A1 (en) *	2000-05-23	2001-12-03	The Rockefeller University	C1 bacteriophage lytic system
US20030036643A1 (en) *	2000-09-14	2003-02-20	Jin Cheng He	Methods and compositions for the construction and use of fusion libraries
PL195815B1 (pl) *	2002-08-05	2007-10-31	Inst Immunologii I Terapii Dos	Sposób otrzymywania szczepu bakteriofaga o zwiększonym powinowactwie do komórek eukariotycznych, środki go zawierające i zastosowania bakteriofagów
AU2003297269A1 (en) *	2002-11-14	2004-06-15	Gangagen, Inc.	Bacteriophage having modified holin and uses thereof

2004
- 2004-07-20 EP EP04017128A patent/EP1618886A1/de not_active Withdrawn
2005
- 2005-07-20 KR KR1020077003983A patent/KR20070036185A/ko not_active Withdrawn
- 2005-07-20 CA CA002572832A patent/CA2572832A1/en not_active Abandoned
- 2005-07-20 AT AT05772001T patent/ATE466588T1/de not_active IP Right Cessation
- 2005-07-20 EP EP05772001A patent/EP1853291B1/de not_active Expired - Lifetime
- 2005-07-20 EA EA200700346A patent/EA012120B1/ru not_active IP Right Cessation
- 2005-07-20 JP JP2007521953A patent/JP2008506411A/ja active Pending
- 2005-07-20 NZ NZ553196A patent/NZ553196A/en not_active IP Right Cessation
- 2005-07-20 US US11/572,260 patent/US20090117084A1/en not_active Abandoned
- 2005-07-20 CN CNA2005800243303A patent/CN1988913A/zh active Pending
- 2005-07-20 DE DE602005021159T patent/DE602005021159D1/de not_active Expired - Fee Related
- 2005-07-20 AU AU2005263771A patent/AU2005263771A1/en not_active Abandoned
- 2005-07-20 WO PCT/EP2005/053533 patent/WO2006008312A1/en not_active Ceased
2007
- 2007-01-25 NO NO20070485A patent/NO20070485L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20070485L (no)	2007-04-13
JP2008506411A (ja)	2008-03-06
KR20070036185A (ko)	2007-04-02
WO2006008312A1 (en)	2006-01-26
AU2005263771A1 (en)	2006-01-26
CN1988913A (zh)	2007-06-27
EP1853291B1 (de)	2010-05-05
DE602005021159D1 (de)	2010-06-17
CA2572832A1 (en)	2006-01-26
EA200700346A1 (ru)	2007-10-26
EP1853291A1 (de)	2007-11-14
EA012120B1 (ru)	2009-08-28
US20090117084A1 (en)	2009-05-07
NZ553196A (en)	2009-08-28
EP1618886A1 (de)	2006-01-25

Similar Documents

Publication	Publication Date	Title
JOP20220079A1 (ar)	2023-01-30	بروتين ربط متعددة الخصوصية لمعالجة السرطان
ATE481978T1 (de)	2010-10-15	Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
HUP0002095A2 (hu)	2000-10-28	Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DE602004029393D1 (de)	2010-11-11	Tgf-beta1-bindende und geträgerte peptide
ES2173922T3 (es)	2002-11-01	Polipeptidos de la familia del gen de la semaforina.
CY1108459T1 (el)	2013-09-04	Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
ATE354638T1 (de)	2007-03-15	Menschlicher gewebsinhibitor von metalloproteinase-4
WO2021133959A3 (en)	2021-08-12	Compositions and methods for gamma delta tcr reprogramming using fusion proteins
MXPA05008704A (es)	2005-10-05	Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
BRPI0509278A (pt)	2007-09-18	polipeptìdeo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira isolada, linhagem de célula empacotadora, dispositivo celular biocompatìvel implantável, composição farmacêutica, uso do polipeptìdeo, ou da seqüência de ácido nucléico isolada, ou do vetor de expressão, ou de uma composição de células hospedeiras, ou de um dispositivo celular biocompatìvel implantável ou de uma linhagem de célula empacotadora, método de tratamento de uma condição patológica em um indivìduo, métodos para prevenir a apoptose em uma célula neuronal de mamìfero, para realçar a sobrevivência de uma célula neuronal de mamìfero, para gerar um neurÈnio, para expandir uma composição de células de mamìfero, e para diferenciar uma composição de células de mamìfero, anticorpo, e, imunoconjugado
DE69635349D1 (de)	2005-12-01	Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
BRPI0515604A (pt)	2008-07-29	método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
WO2005086835A3 (en)	2006-12-21	Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
EP0232523A3 (en)	1988-12-07	Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
BR9700957A (pt)	1998-12-08	Proteína de hormónio de crescimento humano mutante deoxiribonucleotídeo peptídeo de uma proteína plasmídeo de expressão produto anticorpo medicamentos para o tratamento de gigantismo e acromegalia e para terapia genética
EP1499190A4 (de)	2005-06-15	Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
NZ562436A (en)	2010-01-29	Toll-like receptor 14 (TLR14) and use thereof
ATE466588T1 (de)	2010-05-15	Bakteriophagen- und prophagen-proteine in der krebsgentherapie
ATE534902T1 (de)	2011-12-15	Replikationsproteinn ciz1
ATE368687T1 (de)	2007-08-15	Thrombopoietinproteine mit verbesserten eigenschaften
AR053285A1 (es)	2007-04-25	Tratamiento de enfemedades usando un sistema mejorado de expresion regulada
WO2002014369A3 (en)	2002-09-12	Human kininogen d5 domain polypeptides and their use
GT200600210A (es)	2007-01-03	Terapia genica de interferon-beta usdando un sistema mejorado de expresion regulada
ATE496129T1 (de)	2011-02-15	Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
WO2002038188A3 (de)	2002-12-12	Verwendung der humanen lrp/mvp promotors für einen therapie-induzierbaren vektor

Legal Events

Date	Code	Title	Description
2010-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties